Actively Recruiting
Biomarkers for Prediction of Tumor Response to Radiotherapy
Led by Chuangzhen Chen · Updated on 2024-02-06
100
Participants Needed
1
Research Sites
422 weeks
Total Duration
On this page
Sponsors
C
Chuangzhen Chen
Lead Sponsor
U
University of Oxford
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to explore potential biomarkers for prediction of therapeutic outcomes in patients with solid tumors after radiotherapy
CONDITIONS
Official Title
Biomarkers for Prediction of Tumor Response to Radiotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathological proven diagnosis of solid tumors
- Tumor accessible for biopsy during the course of radiotherapy or tumor samples could be obtained via surgery
- Patient must provide study-specific informed consent prior to study entry
You will not qualify if you...
- History of autoimmune diseases
- History of immunotherapy
- Prior radiation therapy that would result in overlap of planned radiation therapy fields
- Will receive immunotherapy during the course of radiotherapy
- Contraindications for biopsy, such as high bleeding risk
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cancer Hospital, Shantou University Medical College
Shantou, Guangdong, China, 515031
Actively Recruiting
Research Team
C
Chuangzhen Chen, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here